How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses

Vinay Prasad; Sham Mailankody

doi:10.1182/blood-2015-07-657478

How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses

Vinay Prasad, Sham Mailankody

Knight Cancer Institute

Research output: Contribution to journal › Letter › peer-review

15 Scopus citations

Original language	English (US)
Pages (from-to)	1860-1861
Number of pages	2
Journal	Blood
Volume	126
Issue number	15
DOIs	https://doi.org/10.1182/blood-2015-07-657478
State	Published - Oct 8 2015

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2015-07-657478

Cite this

@article{cadce5ed86dc40558f0148602b623604,

title = "How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses",

author = "Vinay Prasad and Sham Mailankody",

year = "2015",

month = oct,

day = "8",

doi = "10.1182/blood-2015-07-657478",

language = "English (US)",

volume = "126",

pages = "1860--1861",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "15",

}

TY - JOUR

T1 - How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses

AU - Prasad, Vinay

AU - Mailankody, Sham

PY - 2015/10/8

Y1 - 2015/10/8

UR - http://www.scopus.com/inward/record.url?scp=84943599112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943599112&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-07-657478

DO - 10.1182/blood-2015-07-657478

M3 - Letter

C2 - 26320099

AN - SCOPUS:84943599112

SN - 0006-4971

VL - 126

SP - 1860

EP - 1861

JO - Blood

JF - Blood

IS - 15

ER -

How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this